Imagenetix Plans Joint Health Study

Imagenetix Plans Joint Health Study

KEARNY, N.J.A new study on the joint health ingredient Celadrin®has been commissioned by Imagenetix Inc. (www.imagenetix.com), Celadrinsdeveloper, according to Proprietary Nutritionals Inc. (www.celadrin.com),marketers of the ingredient. Patients with moderate to severe knee pain arecurrently being enrolled in the study, which is being conducted by a privateclinical trials facility.Test subjects will be randomized to receive capsules ofCeladrin or placebo during the 60-day, double blind, placebo-controlled,multi-center trial, which is expected to be completed this summer.

Dean Mosca, president of Proprietary Nutritionals, said, Celadrin has beenproven to work faster than other natural ingredients and doesnt have the sideeffects of drugs. Since it addresses a wide range of joint, muscle andtendonrelated ailments, it has gained solid market share in the $22 billionjoint health market.